Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model
- PMID: 2306753
- PMCID: PMC11038853
- DOI: 10.1007/BF01742492
Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model
Abstract
We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (approximately 80%) of the mice that underwent s.c. C-26 tumor excision systemic treatment with low-dose rIL-2 (3 x 10(4) U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 x 10(4) U/day) led to 53% survival (P less than 0.001). Both LAK cells and C-26-tumor-immune lymphocytes given during rIL-2-treatment significantly increased the effects of rIL-2 at the low but not at the high-dose, with tumor-immune effectors resulting in the highest percentage (63%) of cures. When mice bearing 3-day artificial lung metastases of C-26 cells were treated wtih low- or high-dose rIL-2, in combination with or without LAK or tumor-immune lymphocytes, a highly significant reduction or abrogation of the number of lung foci was observed with all treatments, including those involving or tumor-immune lymphocytes alone. Assessment of survival benefit in these mice, however, showed survival prolongation, with 20% cures achieved by low-dose rIL-2 alone and up to 65% cures by LAK in combination with low-dose rIL-2. In this system of artificial metastasis high-dose rIL-2 alone increased the survival time but failed to cure the animals, and the addition of LAK was ineffective whereas that of tumor-immune lymphocytes led to 80% cure. These results suggest that tumor-immune lymphocytes are more effective than LAK when combined with rIL-2 and that caution is necessary in extrapolating findings obtained in artificial metastasis models.
Similar articles
-
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.Cancer Res. 1986 Feb;46(2):676-83. Cancer Res. 1986. PMID: 3484431
-
Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.Ann Ist Super Sanita. 1990;26(3-4):423-32. Ann Ist Super Sanita. 1990. PMID: 2091504
-
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.Cancer Res. 1986 Oct;46(10):4973-8. Cancer Res. 1986. PMID: 3489517
-
Adoptive therapies: quo vadis?Pathol Immunopathol Res. 1988;7(6):442-58. doi: 10.1159/000157074. Pathol Immunopathol Res. 1988. PMID: 3070530 Review.
-
Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.Cancer Immunol Immunother. 1993;36(3):141-8. doi: 10.1007/BF01741084. Cancer Immunol Immunother. 1993. PMID: 8439974 Free PMC article. Review.
Cited by
-
Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.Cancer Immunol Immunother. 1991;34(1):53-62. doi: 10.1007/BF01741325. Cancer Immunol Immunother. 1991. PMID: 1760812 Free PMC article.
-
Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.Cancer Sci. 2007 Mar;98(3):416-23. doi: 10.1111/j.1349-7006.2006.00385.x. Cancer Sci. 2007. PMID: 17270031 Free PMC article.
-
Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2.Cancer Immunol Immunother. 1991;33(5):346-9. doi: 10.1007/BF01756601. Cancer Immunol Immunother. 1991. PMID: 1868493 Free PMC article.
-
7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.Cancer Immunol Immunother. 1994 Feb;38(2):83-91. doi: 10.1007/BF01526202. Cancer Immunol Immunother. 1994. PMID: 8306370 Free PMC article.
References
-
- Brattain MG, Strobel-Stevens J, Five D, Webb M, Sarrif AM. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 1980;40:2142. - PubMed
-
- Chou T, Chang AE, Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. J Immunol. 1988;140:2453. - PubMed
-
- Fisher B, Packard BS, Read EJ, Carasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol. 1989;7:250. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources